The role of the TGF-β coreceptor endoglin in cancer

TheScientificWorldJournal

Volumn 10, Issue , 2010, Pages 2367-2384

  Pérez Gómez, Eduardo ^a,e   Del Castillo, Gaelle ^a   Santibáñez, Juan Francisco ^b   López Novoa, Jose Miguel ^c   Bernabéu, Carmelo ^d   Quintanilla, Miguel ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^e UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Angiogenesis; Cancer; Endoglin (CD105); Invasion; Malignant progression; Migration; TGF

Indexed keywords

ANTIBODY; BINDING PROTEIN; CARCINOGEN; DIMETHYLBENZ[A]ANTHRACENE; ENDOGLIN; ENDOGLIN ANTIBODY; MATRIX METALLOPROTEINASE 14; MEMBRANE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRC 105; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANGIOGENESIS; BREAST CANCER; CANCER CELL; CANCER INVASION; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; DISEASE COURSE; DRUG TARGETING; DRUG TOLERABILITY; ENDOCYTOSIS; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGUS CARCINOMA; EWING SARCOMA; FAMILIAL CANCER; FAMILIAL POLYPOSIS; GENE MUTATION; GENETIC PREDISPOSITION; HAMARTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; JUVENILE POLYPOSIS; LEUKEMIA; MELANOMA; METASTASIS; MICROVASCULATURE; NEOPLASM; NONHUMAN; PROSTATE CANCER; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW; SKIN CANCER; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR GROWTH; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIGENS, CD; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; PROTEIN BINDING; RECEPTORS, CELL SURFACE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION;

EID: 78650255998     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2010.230     Document Type: Review

References (113)

1. Gordon, K.J. and Blobe, G.C. (2008) Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim. Biophys. Acta 1782, 197-228.
2. Padua, D. and Massague, J. (2009) Roles of TGF beta in metastasis. Cell Res. 19, 89-102.
3. Derynck, R. and Zhang, Y.E. (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425, 577-584.
4. Zavadil, J. and Bottinger, E.P. (2005) TGF-beta and epithelial-to- mesenchymal transitions. Oncogene 24, 5764-5774.
5. Zhang, Y.E. (2009) Non-Smad pathways in TGF-beta signaling. Cell Res. 19, 128-139.
6. Hahn, W.C. and Weinberg, R.A. (2002) Modelling the molecular circuitry of cancer. Nat. Rev. Cancer 2, 331-341.
7. Levy, L. and Hill, C.S. (2006) Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 17, 41-58.
8. Seoane, J. (2006) Escaping from the TGF-beta anti-proliferative control. Carcinogenesis 27, 2148-2156.
9. Derynck, R., Akhurst, R.J., and Balmain, A. (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 29, 117-129. (Pubitemid 32952643)
10. Massague, J. (2008) TGF beta in cancer. Cell 134, 215-230.
11. Ikushima, H. and Miyazono, K. (2010) TGF beta signalling: a complex web in cancer progression. Nat. Rev. Cancer 10, 415-424.
12. Thiery, J.P., Acloque, H., Huang, R.Y.J., and Nieto, M.A. (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890.
13. Lopez-Novoa, J.M. and Nieto, M.A. (2009) Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol. Med. 1, 303-314.
14. Gougos, A. and Letarte, M. (1990) Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J. Biol. Chem. 265, 8361-8364.
15. Gougos, A., St Jacques, S., Greaves, A., Oconnell, P.J., D'Apice, A.J.F., Buhring, H.J., Bernabeu, C., Vanmourik, J.A., and Letarte, M. (1992) Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial-cells, leukemic-cells, and syncytiotrophoblasts. Int. Immunol. 4, 83-92.
16. Moren, A., Ichijo, H., and Miyazono, K. (1992) Molecular cloning and characterization of the human and porcine transforming growth-factor-beta type-III Receptors. Biochem. Biophys. Res. Commun. 189, 356-362.
17. Bellon, T., Corbi, A., Lastres, P., Cales, C., Cebrian, M., Vera, S., Cheifetz, S., Massague, J., Letarte, M., and Bernabeu, C. (1993) Identification and expression of 2 forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur. J. Immunol. 23, 2340-2345. (Pubitemid 23265903)
18. Bork, P. and Sander, C. (1992) A large domain common to sperm receptors (Zp2 and Zp3) and TGF-beta type-III receptor. FEBS Lett. 300, 237-240.
19. Jovine, L., Darie, C.C., Litscher, E.S., and Wassarman, P.M. (2005) Zona pellucida domain proteins. Annu. Rev. Biochem. 74, 83-114.
20. Llorca, O., Trujillo, A., Blanco, F.J., and Bernabeu, C. (2007) Structural model of human endoglin, a transmembrane receptor responsible for hereditary hemorrhagic telangiectasia. J. Mol. Biol. 365, 694-705.
21. Koleva, R.I., Conley, B.A., Romero, D., Riley, K.S., Marto, J.A., Lux, A., and Vary, C.P.H. (2006) Endoglin structure and function - determinants of endoglin phosphorylation by transforming growth factor-beta receptors. J. Biol. Chem. 281, 25110-25123.
22. Perez-Gomez, E., Eleno, N., Lopez, J.M., Ramirez, J.R., Velasco, B., Letarte, M., Bernabeu, C., and Quintanilla, M. (2005) Characterization of murine S-endoglin isoform and its effects on tumor development. Oncogene 24, 4450-4461.
23. Feng, X.H. and Derynck, R. (2005) Specificity and versatility in TGF-beta signaling through Smads. Annu. Rev. Cell Dev. Biol. 21, 659-693.
24. Massague, J. and Gomis, R.R. (2006) The logic of TGF beta signaling. FEBS Lett. 580, 2811-2820.
25. Massague, J. (1998) TGF-beta signal transduction. Annu. Rev. Biochem. 67, 753-791.
26. Lopez-Casillas, F., Cheifetz, S., Doody, J., Andres, J.L., Lane, W.S., and Massague, J. (1991) Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell 67, 785-795. (Pubitemid 121001491)
27. Esparza-Lopez, J., Montiel, J.L., Vilchis-Landeros, M.M., Okadome, T., Miyazono, K., and Lopez-Casillas, F. (2001) Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily - specialized binding regions for transforming growth factor-beta and inhibin A. J. Biol. Chem. 276, 14588-14596.
28. Cheifetz, S., Bellon, T., Cales, C., Vera, S., Bernabeu, C., Massague, J., and Letarte, M. (1992) Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J. Biol. Chem. 267, 19027-19030.
29. Letamendia, A., Lastres, P., Botella, L.M., Raab, U., Langa, C., Velasco, B., Attisano, L., and Bernabeau, C. (1998) Role of endoglin in cellular responses to transforming growth factor beta -- a comparative study with betaglycan. J. Biol. Chem. 273, 33011-33019.
30. Barbara, N.P., Wrana, J.L., and Letarte, M. (1999) Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J. Biol. Chem. 274, 584-594.
31. Scharpfenecker, M., van Dinther, M., Liu, Z., van Bezooijen, R.L., Zhao, Q.H., Pukac, L., Lowik, C.W.G.M., and ten Dijke, P. (2007) BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J. Cell Sci. 120, 964-972.
32. Guerrero-Esteo, M., Sanchez-Elsner, T., Letamendia, A., and Bernabeu, C. (2002) Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J. Biol. Chem. 277, 29197-29209.
33. Bernabeu, C., Conley, B.A., and Vary, C.P.H. (2007) Novel biochemical pathways of endoglin in vascular cell physiology. J. Cell. Biochem. 102, 1375-1388.
34. Fonsatti, E., Nicolay, H.J.M., Altomonte, M., Covre, A., and Maio, M. (2010) Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc. Res. 86, 12-19.
35. Lebrin, F. and Mummery, C.L. (2008) Endoglin-mediated vascular remodeling: mechanisms underlying hereditary hemorrhagic telangiectasia. Trends Cardiovas. Med. 18, 25-32.
36. Fonsatti, E., Del Vecchio, L., Altomonte, M., Sigalotti, L., Nicotra, M.R., Coral, S., Natali, P.G., and Maio, M. (2001) Endoglin: an accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J. Cell. Physiol. 188, 1-7.
37. Bernabeu, C., Lopez-Novoa, J.M., and Quintanilla, M. (2009) The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim. Biophys. Acta 1792, 954-973.
38. Fonsatti, E., Jekunen, A.P., Kairemo, K.J.A., Coral, S., Snellman, M., Nicotra, M.R., Natali, P.G., Altomonte, M., and Maio, M. (2000) Endoglin is a suitable target for efficient imaging of solid tumors: In vivo evidence in a canine mammary carcinoma model. Clin. Cancer Res. 6, 2037-2043.
39. Bredow, S., Lewin, M., Hofmann, B., Marecos, E., and Weissleder, R. (2000) Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. Eur. J. Cancer 36, 675-681.
40. Costello, B., Chenggang, L.G., Duff, S., Butterworth, D., Khan, A., Perkins, M., Owens, S., Al-Mowallad, A.F., O'Dwyer, S.O., and Kumar, S. (2004) Perfusion of Tc-99(m)-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target. Int. J. Cancer 109, 436-441.
41. Beresford, M.J., Harris, A.L., Ah-See, M., Daley, F., Padhani, A.R., and Makris, A. (2006) The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer. Br. J. Cancer 95, 1683-1688. (Pubitemid 44950794)
42. Korpanty, G., Grayburn, P.A., Shohet, R.V., and Brekken, R.A. (2005) Targeting vascular endothelium with avidin microbubbles. Ultrasound Med. Biol. 31, 1279-1283.
43. Folkman, J. (1996) New perspectives in clinical oncology from angiogenesis research. Eur. J. Cancer 32A, 2534-2539.
44. Seon, B.K., Haba, A., Matsuno, F., Takahashi, N., Tsujie, M., She, X., Harada, N., Uneda, S., Tsujie, T., Toi, H., Tsai, H., Haruta, Y. (2010) Endoglin-targeted cancer therapy. Curr. Drug Deliv. [Epub ahead of print]
45. Zbuk, K.M. and Eng, C. (2007) Hamartomatous polyposis syndromes. Nat. Clin. Pract. Gastr. Hepatol. 4, 492-502.
46. Calva, D. and Howe, J.R. (2008) Hamartomatous polyposis syndromes. Surg. Clin. North Am. 88, 779-817.
47. Horrilleno, E.G., Eckert, C., and Ackerman, L.V. (1957) Polyps of the rectum and colon in children. Cancer 10, 1210-1220.
48. Howe, J.R., Mitros, F.A., Summers, R.W. (1998) The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann. Surg. Oncol. 5, 751-756.
49. Brosens, L.A.A., van Hattem, A., Hylind, L.M., Iacobuzio-Donahue, C., Romans, K.E., Axilbund, J., Cruz-Correa, M., Tersmette, A.C., Offerhaus, G.J.A., and Giardiello, F.M. (2007) Risk of colorectal cancer in juvenile polyposis. Gut 56, 965-967.
50. Howe, J.R., Sayed, M.G., Ahmed, A.F., Ringold, J., Larsen-Haidle, J., Merg, A., Mitros, F.A., Vaccaro, C.A., Petersen, G.M., Giardiello, F.M., Tinley, S.T., Aaltonen, L.A., and Lynch, H.T. (2004) The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. J. Med. Genet. 41, 484-491.
51. Sayed, M.G., Ahmed, A.F., Ringold, J.R., Anderson, M.E., Bair, J.L., Mitros, F.A., Lynch, H.T., Tinley, S.T., Petersen, G.M., Giardiello, F.M., Vogelstein, B., and Howe, J.R. (2002) Germline SMAD4 or BMPR1A mutations and phenotype of juvenile polyposis. Ann. Surg. Oncol. 9, 901-906.
52. Friedl, W., Uhlhaas, S., Schulmann, K., Stolte, M., Loff, S., Back, W., Mangold, E., Stern, M., Knaebel, H.P., Sutter, C., Weber, R.G., Pistorius, S., Burger, B., and Propping, P. (2002) Juvenile polyposis: massive gastric polyposis is more common in MADH4 mutation carriers than in BMPR1A mutation carriers. Hum. Genet. 111, 108-111.
53. Gallione, C.J., Repetto, G.M., Legius, E., Rustgi, A.K., Schelley, S.L., Tejpar, S., Mitchell, G., Drouin, E., Westermann, C.J.J., and Marchuk, D.A. (2004) A combined syndrome of juvenile polyposis and hereditary haemorrhagic telanglectasia associated with mutations in MADH4 (SMAD4). Lancet 363, 852-859.
54. Gallione, C.J., Richards, J.A., Letteboer, T.G.W., Rushlow, D., Prigoda, N.L., Leedom, T.P., Ganguly, A., Castells, A., van Amstel, J.K.P., Westermann, C.J.J., Pyeritz, R.E., and Marchuk, D.A. (2006) SMAD4 mutations found in unselected HHT patients. J. Med. Genet. 43, 793-797.
55. Gallione, C., Aylsworth, A.S., Beis, J., Berk, T., Bernhardt, B., Clarks, R.D., Clericuzio, C., Danesino, C., Drautz, J., Fahl, J., Fan, Z., Faughnan, M.E., Ganguly, A., Garvie, J., Henderson, K., Kini, U., Leedom, T., Ludman, M., Lux, A., Maisenbacher, M., Mazzucco, S., Olivieri, C., van Amstel, J.K.P., Prigoda-Lee, N., Pyeritz, R.E., Reardon, W., Vandezande, K., Waldman, J.D., White, R.I., Williams, C.A., and Marchuk, D.A. (2010) Overlapping spectra of SMAD4 mutations in juvenile polyposis (JP) and JP-HHT syndrome. Am. J. Med. Genet. A 152A, 333-339.
56. Sweet, K., Willis, J., Zhou, X.P., Gallione, C., Sawada, T., Alhopuro, P., Khoo, S.K., Patocs, A., Martin, C., Bridgeman, S., Heinz, J., Pilarski, R., Lehtonen, R., Prior, T.W., Frebourg, T., Teh, B.T., Marchuk, D.A., Aaltonen, L.A., and Eng, C. (2005) Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA 294, 2465-2473.
57. Howe, J.R., Haidle, J.L., Lal, G., Bair, J., Song, C., Pechman, B., Chinnathambi, S., and Lynch, H.T. (2007) ENG mutations in MADH4/BMPR1A mutation negative patients with juvenile polyposis. Clin. Genet. 71, 91-92.
58. Kassouf, W., Ismail, H.R.A., Aprikian, A.G., and Chevalier, S. (2004) Whole-mount prostate sections reveal differential endoglin expression in stromal, epithelial, and endothelial cells with the development of prostate cancer. Prostate Cancer Prostatic Dis. 7, 105-110.
59. Liu, Y.Q., Jovanovic, B., Pins, M., Lee, C., and Bergan, R.C. (2002) Overexpression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion. Oncogene 21, 8272-8281.
60. Lakshman, M., Huang, X., Ananthanarayanan, V., Jovanovic, B., Liu, Y., Craft, C.S., Romero, D., Vary, C.P., and Bergan, R.C. (2010) Endoglin suppresses human prostate cancer metastasis. Clin. Exp. Metastasis [Epub ahead of print]
61. Jovanovic, B.D., Huang, S., Liu, Y., Naguib, K.N., and Bergan, R.C. (2001) A simple analysis of gene expression and variability in gene arrays based on repeated observations. Am. J. Pharmacogenomics 1, 145-152.
62. Wong, V.C.L., Chan, P.L., Bernabeu, C., Law, S., Wang, L.D., Li, J.L., Tsao, S.W., Srivastava, G., and Lung, M.L. (2008) Identification of an invasion and tumor-suppressing gene, endoglin (ENG), silenced by both epigenetic inactivation and allelic loss in esophageal squamous cell carcinoma. Int. J. Cancer 123, 2816-2823.
63. Fernandez-Ruiz, E., St Jacques, S., Bellon, T., Letarte, M., and Bernabeu, C. (1993) Assignment of the human endoglin gene (End) to 9Q34.qter Cytogenet. Cell Genet. 64, 204-207.
64. Yang, L.C., Leung, A.C.C., Ko, J.M.Y., Lo, P.H.Y., Tang, J.C.O., Srivastava, G., Oshimura, M., Stanbridge, E.J., Daigo, Y., Nakamura, Y., Tang, C.M.C., Lau, K.W., Law, S., and Lung, M.L. (2005) Tumor suppressive role of a 2.4Mb 9q33-q34 critical region and DEC1 in esophageal squamous cell carcinoma. Oncogene 24, 697-705.
65. Leung, A.C.C., Wong, V.C.L., Yang, L.C., Chan, P.L., Daigo, Y., Nakamura, Y., Qi, R.Z., Miller, L.D., Liu, E.T.B., Wang, L.D., Li, J.L., Law, S., Tsao, S.W., and Lung, M.L. (2008) Frequent decreased expression of candidate tumor suppressor gene, DEC1, and its anchorage-independent growth properties and impact on global gene expression in esophageal carcinoma. Int. J. Cancer 122, 587-594.
66. Henry, L., Johnson, D., Sarrió, D., Lee, S., Quinlan, P., Crook, T., Thompson, A., Reis-Filho, J.S, and Isacke, C.M. (2010) Endoglin expression in breast tumor cells suppresses invasion and metastasis and correlates with improved clinical outcome. Oncogene [Epub ahead of print]
67. Oxmann, D., Held-Feindt, J., Stark, A.M., Hattermann, K., Yoneda, T., and Mentlein, R. (2008) Endoglin expression in metastatic breast cancer cells enhances their invasive phenotype. Oncogene 27, 3567-3575.
68. Pardali, E., van der Schaft, D.W.J., Wiercinska, E., Gorter, A., Hogendoorn, P.C.W., Griffioen, A.W., and ten Dijke, P. (2010) Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma. Oncogene [Epub ahead of print]
69. Postiglione, L., Di Domenico, G., Caraglia, M., Marra, M., Giuberti, G., Del Vecchio, L., Montagnani, S., Macri, M., Bruno, E.M., Abbruzzese, A., and Rossi, G. (2005) Differential expression and cytoplasm/membrane distribution of endoglin (CD105) in human tumour cell lines: implications in the modulation of cell proliferation. Int. J. Oncol. 26, 1193-1201.
70. Guerrero-Esteo, M., Lastres, P., Letamendia, A., Perez-Alvarez, M.J., Langa, C., Lopez, L.A., Fabra, A., Garcia-Pardo, A., Vera, S., Letarte, M., and Bernabeu, C. (1999) Endoglin overexpression modulates cellular morphology, migration, and adhesion of mouse fibroblasts. Eur. J. Cell Biol. 78, 614-623.
71. Sanz-Rodriguez, F., Guerrero-Esteo, M., Botella, L.M., Banville, D., Vary, C.P.H., and Bernabeu, C. (2004) Endoglin regulates cytoskeletal organization through binding to ZRP-1, a member of the Lim family of proteins. J. Biol. Chem. 279, 32858-32868.
72. Conley, B.A., Koleva, R., Smith, J.D., Kacer, D., Zhang, D.W., Bernabeu, C., and Vary, C.P.H. (2004) Endoglin controls cell migration and composition of focal adhesions - function of the cytosolic domain. J. Biol. Chem. 279, 27440-27449.
73. Lee, N.Y. and Blobe, G.C. (2007) The interaction of endoglin with beta-arrestin2 regulates transforming growth factor-beta-mediated ERK activation and migration in endothelial cells. J. Biol. Chem. 282, 21507-21517.
74. Lee, N.Y., Ray, B., How, T., and Blobe, G.C. (2008) Endoglin promotes transforming growth factor beta-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC. J. Biol. Chem. 283, 32527-32533.
75. Ray, B.N., Lee, N.Y., How, T., and Blobe, G.C. (2010) ALK5 phosphorylation of the endoglin cytoplasmic domain regulates Smad1/5/8 signaling and endothelial cell migration. Carcinogenesis 31, 435-441.
76. Craft, C.S., Romero, D., Vary, C.P.H., and Bergan, R.C. (2007) Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. Oncogene 26, 7240-7250.
77. Craft, C.S., Xu, L., Romero, D., Vary, C.P.H., and Bergan, R.C. (2008) Genistein induces phenotypic reversion of endoglin deficiency in human prostate cancer cells. Mol. Pharmacol. 73, 235-242.
78. Romero, D., Terzic, A., Conley, B.A., Craft, C.S., Jovanovic, B., Bergan, R.C., and Vary, C.P.H. (2010) Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration. Carcinogenesis 31, 359-366.
79. Meng, Q.J., Lux, A., Holloschi, A., Li, J., Hughes, J.M.X., Foerg, T., McCarthy, J.E.G., Heagerty, A.M., Kioschis, P., Hafner, M., and Garland, J.M. (2006) Identification of Tctex2 beta, a novel dynein light chain family member that interacts with different transforming growth factor-beta receptors. J. Biol. Chem. 281, 37069-37080.
80. Muenzner, P., Bachmann, V., Zimmermann, W., Hentschel, J., and Hauck, C.R. (2010) Human-restricted bacterial pathogens block shedding of epithelial cells by stimulating integrin activation. Science 239, 1197-1201.
81. Wipff, J., Avouac, J., Borderie, D., Zerkak, D., Lemarechal, H., Kahan, A., Boileau, C., and Allanore, Y. (2008) Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatology 47, 972-975.
82. Venkatesha, S., Toporsian, M., Lam, C., Hanai, J., Mammoto, T., Kim, Y.M., Bdolah, Y., Lim, K.H., Yuan, H.T., Libermann, T.A., Stillman, I.E., Roberts, D., D'Amore, P.A., Epstein, F.H., Sellke, F.W., Romero, R., Sukhatme, V.P., Letarte, M., and Karumanchi, S.A. (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 12, 642-649. (Pubitemid 43865232)
83. Li, C.G., Guo, B.Q., Wilson, P.B., Stewart, A., Byrne, G., Bundred, N., and Kumar, S. (2000) Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int. J. Cancer 89, 122-126.
84. Takahashi, N., Kawanishi-Tabata, R., Haba, A., Tabata, M., Haruta, Y., Tsai, H., and Seon, B.K. (2001) Association of serum endoglin with metastasis in patients with colorectal, breast, and ether solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin. Cancer Res. 7, 524-532.
85. Vo, M.N., Evans, M., Leitzel, K., Ali, S.M., Wilson, M., Demers, L., Evans, D.B., and Lipton, A. (2010) Elevated plasma endoglin (CD105) predicts decreased response and survival in a metastatic breast cancer trial of hormone therapy. Breast Cancer Res. Treat. 119, 767-771.
86. Fujita, K., Ewing, C.M., Chan, D.Y.S., Mangold, L.A., Partin, A.W., Isaacs, W.B., and Pavlovich, C.P. (2009) Endoglin (CD105) as a urinary and serum marker of prostate cancer. Int. J. Cancer 124, 664-669.
87. Karam, J.A., Svatek, R.S., Karakiewicz, P.I., Gallina, A., Roehrborn, C.G., Slawin, K.M., and Shariat, S.F. (2008) Use of preoperative plasma endoglin for prediction of lymph node metastasis ion patients with clinically localized prostate cancer. Clin. Cancer Res. 14, 1418-1422.
88. Svatek, R.S., Karam, J.A., Roehrborn, C.G., Karakiewicz, P.I., Slawin, K.M., and Shariat, S.F. (2008) Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. Clin. Cancer Res. 14, 3362-3366.
89. Calabro, L., Fonsatti, E., Bellomo, G., Alonci, A., Colizzi, F., Sigalotti, L., Altomonte, M., Musolino, C., and Maio, M. (2003) Differential levels of soluble endoglin (CD105) in myeloid malignancies. J. Cell. Physiol. 194, 171-175.
90. Mysliwiec, P., Pawlak, K., Bandurski, R., and Kedra, B. (2009) Soluble angiogenesis markers in gastric tumor patients. Folia Histochem. Cytobiol. 47, 81-86.
91. Mysliwiec, P., Pawlak, K., Kuklinski, A., and Kedra, B. (2008) Combined perioperative plasma endoglin and VEGF-A assessment in colorectal cancer patients. Folia Histochem. Cytobiol. 46, 487-492.
92. Odegaard, E., Davidson, B., Engh, V., Onsrud, M., and Staff, A.C. (2008) Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary. Am. J. Obstet. Gynecol. 199, 533.e1-533.e8.
93. Furstenberger, G., von Moos, R., Lucas, R., Thurlimann, B., Senn, H.J., Hamacher, J., and Boneberg, E.M. (2006) Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br. J. Cancer 94, 524-531.
94. Bellone, G., Solerio, D., Chiusa, L., Brondino, G., Carbone, A., Prati, A., Scirelli, T., Camandona, M., Palestro, G., and Poli, M.D. (2007) Transforming growth factor-beta binding receptor endoglin (CD105) expression in esophageal cancer and in adjacent nontumorous esophagus as prognostic predictor of recurrence. Ann. Surg. Oncol. 14, 3232-3242.
95. Hawinkels, L.J.A.C., Kuiper, P., Wiercinska, E., Verspaget, H.W., Liu, Z., Pardali, E., Sier, C.F.M., and ten Dijke, P. (2010) Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res. 70, 4141-4150.
96. Fonsatti, E., Altomonte, M., Nicotra, M.R., Natali, P.G., and Maio, M. (2003) Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 22, 6557-6563.
97. Gingery, A., Bahe, E.L., and Gilbert, J.S. (2009) Placental ischemia and breast cancer risk after preeclampsia: tying the knot. Expert Rev. Anticancer Ther. 9, 671-681.
98. Yuspa, S.H. (1998) The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis. J. Dermatol. Sci. 17, 1-7.
99. Kemp, C.J. (2005) Multistep skin cancer in mice as a model to study the evolution of cancer cells. Semin. Cancer Biol. 15, 460-473.
100. Abel, E.L., Angel, J.M., Kiguchi, K., and DiGiovanni, J. (2009) Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. Nat. Protoc. 4, 1350-1362.
101. Luch, A. (2005) Nature and nurture - lessons from chemical carcinogenesis. Nat. Rev. Cancer 5, 113-125.
102. Quintanilla, M., Brown, K., Ramsden, M., and Balmain, A. (1986) Carcinogen-specific mutation and amplification of Ha-Ras during mouse skin carcinogenesis. Nature 322, 78-80.
103. Glick, A., Ryscavage, A., Perez-Lorenzo, R., Hennings, H., Yuspa, S., and Darwiche, N. (2007) The high-risk benign tumor: evidence from the two-stage skin cancer model and relevance for human cancer. Mol. Carcinog. 46, 605-610.
104. Klein-Szanto, A.J. (1997) Neoplastic and preneoplastic lesions of the mouse skin. In Pathology of Neoplasia and Preneoplasia in Rodents 359, 1-19.
105. Akhurst, R.J. and Balmain, A. (1999) Genetic events and the role of TGF-beta in epithelial tumour progression. J. Pathol. 187, 82-90.
106. Li, A.G.Q., Lu, S.L., Han, G.W., Hoot, K.E., and Wang, X.J. (2006) Role of TGF beta in skin inflammation and carcinogenesis. Mol. Carcinog. 45, 389-396.
107. Cui, W., Fowlis, D.J., Bryson, S., Duffie, E., Ireland, H., Balmain, A., and Akhurst, R.J. (1996) TGF-beta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86, 531-542.
108. Quintanilla, M., Ramirez, J.R., Perez-Gomez, E., Romero, D., Velasco, B., Letarte, M., Lopez-Novoa, J.M., and Bernabeu, C. (2003) Expression of the TGF-beta coreceptor endoglin in epidermal keratinocytes and its dual role in multistage mouse skin carcinogenesis. Oncogene 22, 5976-5985.
109. Jerkic, M., Rodriguez-Barbero, A., Prieto, M., Toporsian, M., Pericacho, M., Rivas-Elena, J.V., Obreo, J., Wang, A., Perez-Barriocanal, F., Arevalo, M., Bernabeu, C., Letarte, M., and Lopez-Novoa, J.M. (2006) Reduced angiogenic responses in adult endoglin heterozygous mice. Cardiovasc. Res. 69, 845-854.
110. Perez-Gomez, E., Villa-Morales, M., Santos, J., Fernandez-Piqueras, J., Gamallo, C., Dotor, J., Bernabeu, C., and Quintanilla, M. (2007) A role for endoglin as a suppressor of malignancy during mouse skin carcinogenesis. Cancer Res. 67, 10268-10277.
111. Mercado-Pimentel, M.E., Hubbard, A.D., and Runyan, R.B. (2007) Endoglin and Alk5 regulate epithelial-mesenchymal transformation during cardiac valve formation. Dev. Biol. 304, 420-432.
112. Haddow, S., Fowlis, D.J., Parkinson, K., Akhurst, R.J., and Balmain, A. (1991) Loss of growth-control by TGF-beta occurs at a late stage of mouse skin carcinogenesis and is independent of Ras gene activation. Oncogene 6, 1465-1470.
113. Santibanez, J.F., Pérez-Gómez, E., Fernandez-L, A., Garrido-Martin, E.M., Carnero, A., Malumbres, M., Vary, C.P., Quintanilla, M., and Bernabéu, C. (2010) The TGF-beta co-receptor endoglin modulates the expression and transforming potential of H-Ras. Carcinogenesis [Epub ahead of print]